

CURRICULUM VITAE

George Liamis, MD

2021

CURRICULUM VITAE

George Liamis, MD

Address: Department of Internal Medicine, School of Medicine, University of Ioannina, 45100 Ioannina, Greece

Email: gliamis@uoi.gr

Personal: Born May 13, 1967

1992: Medical Diploma, School of Medicine, University of Thessaloniki, Greece

10/1995-10/2000 : Specialization in Internal Medicine

12/2003: Doctoral Diploma (Ph.D.) in Internal Medicine, University of Ioannina

6/2002 – 10/2005: Junior Consultant in the Department of Internal Medicine, University Hospital of Ioannina

10/2005–6/2011: Lecturer of Internal Medicine, University of Ioannina

6/2011-19/1/2017: Assistant Professor of Internal Medicine, University of Ioannina

19/1/2017-5/4/2021: Associate Professor of Internal Medicine, University of Ioannina

Current Post: Professor of Internal Medicine, University of Ioannina

Membership: Internal Medicine Society of Greece
Hellenic Society of Atherosclerosis
Hellenic Society of Obesity
European Atherosclerosis Society

1/1/2011-1/7/2011: Sabbatical in the Department of Internal Medicine-Nephrology, Erasmus Medical Center, Rotterdam, The Netherlands

Main academic interests

- 1) Acid - base and electrolyte disorders
- 2) Lipid and other metabolic disorders
- 3) Risk factors for atherosclerosis
- 4) Hypertension

PARTICIPATION IN INTERNATIONAL CLINICAL STUDIES :

1. Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease.
2. A phase 3, randomized, double-blind, placebo-controlled, parallel-group study, followed by an open-label continuation period to assess the safety and efficacy of two different regimens of mipomersen in patients with familial hypercholesterolemia and inadequately controlled low-density lipoprotein cholesterol. Study Code: MIPO3801011 / EFC12875
3. STABILITY clinical study. (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY), evaluating the efficacy of its investigational Lp-PLA2 inhibitor darapladib in adults with chronic coronary heart disease (CHD)
4. ATTEMPT trial. { The Aggressive TreatMent of metabolic syndrome without Perceptible diabeTes (ATTEMPT) Trial.} A long-term, randomized, open label, controlled, multicenter, interventional, survival (endpoint) study to establish optimum LDL-C and non-HDL-C levels in patents with dyslipidemia and metabolic syndrome without overt cardiovascular disease or diabetes mellitus in Greece.
5. Multicenter, randomized, double-blind, parallel arm, 6-week study to evaluate the efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with metabolic syndrome and hypercholesterolemia at high risk for coronary heart disease
6. ONTARGET/TRANSCEND clinical study. ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.
7. ECLIPSE study : 24-week, open-label, randomized, multinational, parallel-group study designed to compare the efficacy and safety of force-titrated treatment with rosuvastatin (10-40 mg) with that of atorvastatin (10-80 mg) in high-risk patients with hypercholesterolemia.

8. Multicentre, randomized double blind placebo controlled study regarding the coadministration of ezetimibe and fenofibrate in patients with mixed hyperlipidemia.
9. Phase III, multicentre, randomized double blind placebo controlled study regarding the coadministration of SCH 58235 (10 mg) and atorvastatin in patients with primary hyperlipidemia.
10. XALIA study: a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis
11. FOURIER study: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
12. NAVIGATE ESUS study: A Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS), Comparing Rivaroxaban 15 mg Once Daily With Aspirin 100 mg
13. POSE Study: A European, observational, three-year cohort comparative study on the safety of the fixed-dose combination pravastatin 40mg/fenofibrate 160 mg (Pravafenix®) versus statin alone in real clinical practice.
14. **Egnatia study:** Streptococcus pneumoniae (**pneumococcal**) serotypes in adults hospitalized with radiographically confirmed community **pneumonia**
15. Select Study: Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity
16. Precious study: A randomised, open, phase III, clinical trial with blinded outcome assessment regarding the PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke
17. VESALIUS-CV study: a Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group four-year outcomes study to examine long-term effects of evolocumab in high-risk cardiovascular disease patients without prior heart attack or stroke.

LIST OF PUBLICATIONS

1).**G.Liamis**, E.Bairaktari, M.Elisaf.

Effect of fenofibrate on serum uric acid levels. Am J Kidney Dis 34(3):594, 1999.

2).**G.Liamis**, M.Elisaf.

Syndrome of inappropriate antidiuresis associated with multiple sclerosis. J Neurol Sci 172(1):38-40, 2000.

3).**G.Liamis**, M.Elisaf.

Hypokalemia, hypophosphatemia and hypouricemia due to proximal renal tubular dysfunction in acute myeloid leukemia.Eur J Haematol 64(4):277-8, 2000.

4).**G.Liamis**, E.Rizos, M.Elisaf.

Reversible proximal tubular dysfunction in a patient with acute febrile illness and normal renal function:an evidence towards leptospirosis.Clin Nephrol 53(4):316, 2000.

5).H.Milionis, **G.Liamis**, M.Elisaf.

Hypernatremia in hospitalized patients: a sequel of inadvertent fluid administration. Arch Intern Med 160(10):1521-2, 2000.

6).K.Nakou, **G.Liamis**, M.Elisaf, K.Siamopoulos.

Low normal potassium levels in acute renal failure: evidence of leptospirosis. Infection 28(3):196, 2000.

7).**G.Liamis**, G.Alexandridis, E.Bairaktari, M.Elisaf.

Aminoglycoside-induced metabolic abnormalities. Ann Clin Biochem 37(Pt 4):543-4, 2000.

8).M.Elisaf, K.Nakou, **G.Liamis**, N.Pavlidis.

Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Ann Oncol 11(8):1067-9, 2000.

9).**G.Liamis**, H.Milionis, E.Rizos, K.Siamopoulos, M.Elisaf.

Mechanisms of hyponatraemia in alcohol patients. *Alcohol Alcohol* 35(6):612-6, 2000.

10).G.Liamis, R.Kalaitzidis, M.Elisaf.

Hypernatraemia during correction of hypercalcemia. *Nephron* 86(3):358, 2000.

11).G.Liamis, C.Giannoutsos, M.Elisaf.

Hyperosmolar nonketotic syndrome with hypernatraemia: how can we monitor treatment? *Diabetes Metab* 26(5):403-5, 2000.

12).H.Milionis, G.Liamis, M.Elisaf.

Appropriate treatment of hypernatraemia in diabetic hyperglycaemic hyperosmolar syndrome. *J Intern Med* 249(3):273-6, 2001.

13).H.Milionis, G.Liamis, M.Elisaf.

Hyperosmolar syndrome in a patient with uncontrolled diabetes mellitus. *Am J Kidney Dis* 37(5):E41, 2001.

14).E.Bairaktari, G.Liamis, O.Tsolas, M.Elisaf.

Partially reversible renal tubular damage in patients with obstructive jaundice. *Hepatology* 33(6):1365-9, 2001.

15).G.Alexandridis, G.Liamis, M.Elisaf.

Reversible tubular dysfunction that mimicked Fanconi's syndrome in a patient with anorexia nervosa. *Int J Eat Disord* 30(2):227-30, 2001.

16).M.Elisaf, G.Liamis, E.Liberopoulos, K.Siamopoulos.

Mechanisms of hypocalcemia in alcoholic patients. *Nephron* 89(4):459-60, 2001.

17).G.Liamis, C.Giannoutsos, M.Elisaf.

Acute pancreatitis-induced hypomagnesemia. *Pancreatology* 1:74-76, 2001.

18).A.Kakafika, G.Liamis, M.Elisaf, D.Mikhailidis.

Effect of atorvastatin on serum creatinine levels. *Curr Med Res and Opin* 17(3): 230-231, 2001.

19). H.Milionis, G.Liamis, M.Elisaf.

Plasma sodium changes in the hyperglycaemic state: Clinical aspects of pathophysiology and management. *Int J Diabetes Met* 9 :60-66, 2001.

20). **G.Liamis**, A.Kakafika, E.Bairaktari, G.Miltiadous, V.Tsimihodimos, J.Goudevenos, A.Achimastos, M.Elisaf.

Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia. *Curr Med Res Opin* 18 (3): 125-128, 2002.

21). H.Milionis, **G.Liamis**, M.Elisaf.

The hyponatremic patient: a systematic approach to laboratory diagnosis. *CMAJ* 166(8): 1056-62, 2002.

22). E. Rizos, **G.Liamis**, M.Elisaf.

Multiple metabolic abnormalities in a patient with the syndrome of inappropriate antidiuresis. *Nephron* 91(2):339-40, 2002.

23). E.Bairaktari, K. Seferiadis, **G.Liamis**, N. Psihogios, O. Tsolas, M.Elisaf.

Rhabdomyolysis-related Renal Tubular Damage Studied by Proton Nuclear Magnetic Resonance Spectroscopy Of Urine. *Clin Chem* 48(7):1106-1009, 2002.

24). **G.Liamis**, E.Bairaktari, M.Elisaf.

Hypokalemia due to Fanconi syndrome in a patient with obstructive jaundice. *Nephron* 92(3):711-2, 2002.

25). H.Milionis, E. Rizos, **G.Liamis**, S. Nikas, K.Siamopoulos, M.Elisaf.

Acid-base and electrolyte disturbances in patients with hypercalcemia. *South Med J* 95(11):1280-7, 2002.

26). E.Liberopoulos, **G.Liamis**, M.Elisaf.

Possible cefotaxime-induced Stevens-Johnson syndrome. *Ann Pharmacother* 37(6) :812-4, 2003.

27) G.Miltiadous, **G.Liamis**, Z.Metafratzi, G. Vartholomatos, N. Kolaitis, M.Elisaf.

Subclavian Vein Thrombosis- A case report and review of the literature. *Intern J Angiology* 2003, 13(1):45-48

28) Liamis G, Kalogirou M, Saugos V, Elisaf M. Therapeutic approach in patients with dysnatraemias. *Nephrol Dial Transplant*. 2006;21(6):1564-9

29) Christidis DS, Liberopoulos EN, Kakafika AI, Miltiados GA, Liamis GL, Kakaidi B, Tselepis AD, Cariolou MA, Elisaf MS. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin. *Arch Med Res*. 2007;38(4):403-10.

30) Liamis G, Christidis D, Alexandridis G, Bairaktari E, Madias NE, Elisaf M. Uric acid homeostasis in the evaluation of diuretic-induced hyponatremia. *J Investig Med*. 2007 Jan;55(1):36-44.

31) Liamis G, Mitrogianni Z, Liberopoulos EN, Tsimihodimos V, Elisaf M. Electrolyte disturbances in patients with hyponatremia. *Intern Med*. 2007;46(11):685-90.

32) Liamis G, Tsimihodimos V, Doumas M, Spyrou A, Bairaktari E, Elisaf M. Clinical and laboratory characteristics of hypernatraemia in an internal medicine clinic. *Nephrol Dial Transplant*. 2008; 23(1): 136-43

33) Liamis G, Milionis H, Elisaf M A review of drug induced-hyponatremia. *Am J Kidney Dis*. 2008; 52(1):144-53

34) Liamis G, Milionis H, Elisaf M In reply to drug induced-hyponatremia adding to the list and tramadol-induced hyponatremia . *Am J Kidney Dis* 2008;52(5):1027

35) Liamis G, Milionis H, Elisaf M Blood pressure drug therapy and electrolyte disturbances. *Int J Clin Pract*. 2008;62(10):1572-80

36) Kostapanos M, Liamis G, Elisaf M Features of the metabolic syndrome relating to cardiorenal outcomes.

Commentary on: decreased kidney function as a risk factor for cardiovascular events in subjects with metabolic syndrome – pilot study
Arch Med Sci 2008;4,4:417-423

37) Liamis G. Milionis H., Elisaf M

Drug induced hypocalcemia

J Bone Minel Metab 2009;27(6):635-642

38) Liamis G. Milionis H., Elisaf M

A review of drug induced-hyponatremia.

NDT plus. 2009;2 (5): 336-346

39)) Liamis G. Milionis H., Elisaf M

Medication-induced hypophosphatemia: a review

QJM. 2010 Jul;103(7):449-59

40) Liamis G. Milionis H, Elisaf M

Pharmacologically-induced metabolic acidosis: a review

Drug safety 2010 1;33(5):371-91

41) Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS.

Do Statins Beneficially or Adversely Affect Glucose Homeostasis? Curr Vasc Pharmacol.

Curr Vasc Pharmacol. 2010 Sep;8(5):612-31

42) Liamis G. Milionis HJ, Elisaf M

Endocrine disorders: Causes of hyponatremia not to neglect. Ann Med. 2011 May;43(3):179-87. Review

43) Liamis G. Milionis HJ, Elisaf M.

Hyponatremia in patients with infectious diseases. J Infect. 2011 Nov;63(5):327-35.

44) Hoorn EJ, Liamis G. Zietse R, Zillikens MC.

Hyponatremia and bone: an emerging relationship. Nat Rev Endocrinol. 2011 Oct 25;8(1):33-9

45) Moutzouri E, Liberopoulos EN, Florentin M, Liamis G. Elisaf MS.

Effects of Statin Monotherapy Versus Statin Plus Ezetimibe Combination on Serum Uric Acid Levels. J Cardiovasc Pharmacol Ther. 2013 Jan;18(1):13-8.

46) Gatselis NK, **Liamis G**, Makaritsis KP, Dalekos GN.

Metabolic acidosis during treatment of mushroom poisoning: a diagnostic pitfall. Intern Med. 2012;51(9):1077-80..

47) Liberopoulos EN, Moutzouri E, Rizos CV, Barkas F, **Liamis G**, Elisaf MS.

Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia.

J Cardiovasc Pharmacol Ther. 2013 Mar;18(2):113-8

48) Florentin M, Liberopoulos EN, Rizos CV, Kei AA, **Liamis G**, Kostapanos MS, Elisaf MS.

Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.

Metab Syndr Relat Disord. 2013 Jun;11(3):152-6

49) **Liamis G**, Liberopoulos E, Alexandridis G, Elisaf M.

Hypomagnesemia in a department of internal medicine. Magnes Res. 2012 Dec;25(4):149-58.

50) **Liamis G**, Rodenburg EM, Hofman A, Zietse R, Stricker BH, Hoorn EJ.

Electrolyte disorders in community subjects: prevalence and risk factors. Am J Med. 2013 Mar;126(3):256-63

51) **Liamis G**, Liberopoulos E, Barkas F, Elisaf M.

Spurious electrolyte disorders: a diagnostic challenge for clinicians. Am J Nephrol. 2013;38(1):50-7.

52) **Liamis G**, Filippatos TD, Elisaf M. Treatment of hyponatremia: the role of lixivaptan. Expert Rev Clin Pharmacol. 2014 Jul;7(4):431-41

53) Barkas F, Liberopoulos EN, Kostapanos MS, **Liamis G**, Tziallas D, Elisaf M. Lipid Target Achievement Among Patients With Very High and High Cardiovascular Risk in a Lipid Clinic. Angiology. 2014 May 15. pii: 0003319714535073.

54) Florentin M, **Liamis G**, Elisaf MS

Colonoscopy preparation-induced disorders in renal function and electrolytes. World J Gastrointest Pharmacol Ther. 2014 May 6;5(2):50-4.

55). **Liamis G**, Liberopoulos E, Barkas F, Elisaf M.

Diabetes mellitus and electrolyte disorders. World J Clin Cases. 2014 Oct 16;2(10):488-96

56) Milionis H, **Liamis G**, Elisaf M.

Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.

Expert Opin Biol Ther. 2015 Feb;15(2):287-98

57) Liamis G, Filippatos TD, Elisaf MS

Correction of hypovolemia with crystalloid fluids: Individualizing infusion therapy. Postgrad Med. 2015 May;127(4):405-12

58. Liamis G , Tsimihodimos V, Elisaf M

Hyponatremia in Diabetes Mellitus: Clues to Diagnosis and Treatment. Diabetes Metab. 2015 6:6

59. Liamis G , Elisaf M

Treatment of Hyponatremia: What the Clinician Needs to Know. J. of Nephrology Res. 2015 June 1(1): 19-21

60. Filippatos TD, Liamis G, F. Christopoulou, Elisaf MS. Ten common pitfalls in the evaluation of patients with hyponatremia. European Journal of Internal Medicine 2015 Dec 16. pii: S0953-6205(15)00419-7. doi: 10.1016/j.ejim.2015.11.022.

61. Barkas F, Elisaf M, Liberopoulos E, Klouras E, **Liamis G**, Rizos EC, Statin therapy with or without ezetimibe and the progression to diabetes. Journal of Clinical Lipidology (2016) doi: 10.1016/j.jacl.2015.11.015.

62. Liamis G, Filippatos TD, Elisaf MS. Thiazide-associated hyponatremia in the elderly: what the clinician needs to know. J Geriatr Cardiol. 2016 Feb;13(2):175-82. doi: 10.11909/j.issn.1671-5411.2016.02.001. Review.

63) **Liamis G**, **Filippatos TD**, **Elisaf MS**. Evaluation and treatment of hypernatremia: a practical guide for physicians. *Postgrad Med.* 2016;128(3):299-306. doi: 10.1080/00325481.2016.1147322. Review.

64) **Liamis G**, **Filippatos TD**, **Elisaf MS**. Electrolyte disorders associated with the use of anticancer drugs. *Eur J Pharmacol.* 2016 Apr 15;777:78-87

65) **Filippatos TD**, **Liamis G**, **Elisaf MS**. Ten pitfalls in the proper management of patients with hyponatremia. *Postgrad Med.* 2016 May 6. *Postgrad Med.* 2016 Jun;128(5):516-22. doi: 10.1080/00325481.2016.1186488. Review.

66) **Liamis G**, **Filippatos TD**, **Liontos A**, **Elisaf MS**. Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise. *Hepatol Int.* 2016 Sep;10(5):762-72. doi: 10.1007/s12072-016-9746-1. Review.

67) **Filippatos TD**, **Liamis G**, **Liontos A**, **Elisaf MS**. Hyponatremia in primary adrenal insufficiency: na often overlooked cause of decreased sodium levels. *Int J Nephrol Kidney Failure*2(3): doi <http://dx.doi.org/10.16966/2380-5498.130>

68) **Liamis G**, **Filippatos TD**, **Liontos A**, **Elisaf MS**. MANAGEMENT OF ENDOCRINE DISEASE: Hypothyroidism-associated hyponatremia: Mechanisms, implications and treatment. *Eur J Endocrinol.* 2017 Jan;176(1):R15-R20. Review.

69) **Liamis G**, **Filippatos TD**, **Liontos A**, **Elisaf MS**. Serum osmolal gap in clinical practice: usefulness and limitations. *Postgrad Med.* 2017 Mar 23:1-4.

70) **Christopoulou EC**, **Filippatos TD**, **Megapanou E**, **Elisaf MS**, **Liamis G**. Phosphate imbalance in patients with heart failure. *Heart Fail Rev.* 2017 May;22(3):349-356. doi: 10.1007/s10741-017-9615-6

71) **Filippatos T**, **Tzavella E**, **Rizos C**, **Elisaf M**, **Liamis G**. Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. *Expert Opin Drug Saf.* 2017 Aug 4:1-12. doi: 10.1080/14740338.2017.1361400. [Epub ahead of print]

72) **Filippatos TD**, **Tsimihodimos V**, **Liamis G**, **Elisaf MS**.

SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms. *Diabetes Metab Syndr*. 2017 Aug 11. pii: S1871-4021(17)30268-0. doi: 10.1016/j.dsx.2017.08.003. [Epub ahead of print]

73) Barkas F, Elisaf M, Liberopoulos E, Kalaitzidis R, **Liamis G.** Uric acid and incident chronic kidney disease in dyslipidemic individuals. *Curr Med Res Opin*.2017 Sep 21:1-7. doi: 10.1080/03007995.2017.1372157. [Epub ahead of print]

74) Liontos A, Filippatos TD, Elisaf MS, **Liamis G.** Renal Potassium Homeostasis: A Fresh Look. *Int J Nephrol Kidney Failure*. 3(2): doi <http://dx.doi.org/10.16966/2380-5498.145>

75) Filippatos TD, Makri A, Elisaf MS, **Liamis G.** HYPONATREMIA in the elderly challenges and solutions. *Clin Interv Aging*. 2017 Nov 14;12:1957-1965

76) Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ; **NAVIGATE ESUS Investigators**. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source *N Engl J Med*. 2018 Jun 7;378(23):2191-2201

77. Filippatos T, Elisaf M, **Liamis G.** Pharmacological management of hyponatremia. *Expert Opin Pharmacother*. 2018 Aug 2:1-8.

78. Kasner SE, Swaminathan B, Lavados P, Sharma M, Muir K, Veltkamp R, Ameriso SF, Endres M, Lutsep H, Messé SR, Spence JD, Nedelteshev K, Perera K, Santo G, Olavarria V, Lindgren A, Bangdiwala S, Shoamanesh A, Berkowitz SD, Mundl H, Connolly SJ, Hart RG; **NAVIGATE ESUS Investigators**. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. *Lancet Neurol*. 2018 Sep 28. pii: S1474-4422(18)30319-3.

79. Barkas F, Elisaf M, **Liamis G** High-Density Lipoprotein Cholesterol and Hyponatremia:

An Unsolved Gordian Knot. *Am J Med.* 2019 Feb;132(2):e47-e48.

80. Makri A, Florentin M, Elisaf MS, **Liamis G.**

Significant Weight Loss In A Patient Taking Olmesartan: An Unusual Case Report. *Curr Drug Saf.* 2019

81. Barkas F, Elisaf M, Liberopoulos E, **Liamis G**, Ntzani EE, Rizos EC.

Atherogenic dyslipidemia increases the risk of incident diabetes in statin-treated patients with impaired fasting glucose or obesity. *J Cardiol.* 2019 Sep;74(3):290-295

82 .Barkas F, **Liamis G**, Milionis H. Hyponatremia in Acute Stroke: To Treat or Not to Treat? *J Stroke Cerebrovasc Dis.* 2019 Oct 1:104421

83. Liamis G, Barkas F, Megapanou E, Christopoulou E, Makri A, Makaritsis K, Ntaios G, Elisaf M, Milionis H. Hyponatremia in Acute Stroke Patients: Pathophysiology, Clinical Significance, and Management Options. *Eur Neurol.* 2019 Nov 13:1-9. doi: 10.1159/000504475. [Epub ahead of print]

84. Florentin M, Kostapanos MS, Anagnostis P, **Liamis G.** Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art? *Expert Opin Pharmacother.* 2019;1–14

85. Megapanou E, Florentin M, Milionis H, Elisaf M, **Liamis G.** Drug-Induced Hypophosphatemia: Current Insights. *Drug Saf.* 2019 Nov 27.

86. Barkas F, **Liamis G**, Elisaf M, Anastasiou G, Liberopoulos E. Metabolically healthy obesity and risk of incident type 2 diabetes in 1077 statin-treated individuals: A six-year retrospective study. *European Journal of Preventive Cardiology*

87. Liamis G, Megapanou E, Elisaf M, Milionis H. Hyponatremia-Inducing Drugs. *Front Horm Res.* 2019;52:167-177. doi: 10.1159/000493246. Epub 2019 Jan 15.

88. Parthymos I, **Liamis G**, Dounousi E, Pentheroudakis G, Mauri D, Zarkavelis G, Florentin M. Metabolic consequences of immune checkpoint inhibitors: a new challenge in clinical practice. *Crit Rev Oncol Hematol.* 2020 May 7;151:102979

89. Koumpis E, Florentin M, Hatzimichael E, **Liamis G.** Hyponatremia in Patients with Hematologic Diseases. *J Clin Med.* 2020 Nov 19;9(11):3721.

90. Florentin M, Parthymos I, Agouridis AP, **Liamis G.** Hyperemesis Gravidarum: A Benign Condition of Pregnancy or a Challenging Metabolic Disorder? Eur J Case Rep Intern Med. 2020 Oct 16;7(12):001979.

91. Anastasiou G, Sakka E, Blathra E, Kalivi A, Elisaf M, **Liamis G,** Liberopoulos E. Lipoprotein(a): A Concealed Precursor of Increased Cardiovascular Risk? A Real-World Regional Lipid Clinic Experience. Arch Med Res. 2020 Dec 27:S0188-4409(20)32244-X.